Aesthetic clinics need a duration estimate they can explain and defend. The problem is that product comparisons often mix labeled time frames with individual outcomes, which can set expectations no clinician can promise.
This guide answers how long does Xeomin last vs Botox, shows what the labels support, and explains how duration fits into responsible product selection and sourcing.
What Are Xeomin and Botox Cosmetic?
Xeomin and Botox Cosmetic are prescription botulinum toxin type A products that temporarily reduce activity in targeted muscles. Xeomin contains incobotulinumtoxinA. Botox Cosmetic contains onabotulinumtoxinA.
The current Xeomin prescribing information describes a 150 kDa active neurotoxin without accessory proteins. Botox Cosmetic labeling describes a botulinum toxin type A neurotoxin complex.
A peer-reviewed review of the Xeomin formulation gives additional background. This formulation difference distinguishes the products, but it does not prove that one will last longer for every patient.
How Long Does Xeomin Last vs Botox According to Current Labels?
The labeled duration ranges overlap:
- Xeomin: The typical effect of each treatment lasts up to 12 to 16 weeks, with individual variation.
- Botox Cosmetic: The effect on glabellar lines lasts approximately three to four months.
The current Botox Cosmetic prescribing information limits this duration statement to glabellar lines. Xeomin uses broader upper-facial-line wording, so this is not a perfectly like-for-like comparison.
For patient communication, the supported answer is about three to four months for either product. Neither label establishes a universal duration advantage.
How Long Xeomin Works vs Botox as Results Fade
Results do not stop on a fixed date. A patient may notice movement returning before they feel the cosmetic effect has fully worn off.
When explaining how long Xeomin works vs Botox, separate three points:
- the labeled duration range;
- the patient’s observed return of movement; and
- the clinician’s findings at follow-up.
Start with the labeled range, then compare it with the patient’s actual response. This gives staff a consistent way to discuss duration without turning a population estimate into a personal guarantee.
Xeomin Duration Compared to Botox: A Clinic View
| Decision point | Xeomin | Botox Cosmetic |
| Active ingredient | IncobotulinumtoxinA | OnabotulinumtoxinA |
| Labeled aesthetic duration | Up to 12 to 16 weeks for upper facial lines | Approximately three to four months for glabellar lines |
| Formulation wording | 150 kDa neurotoxin without accessory proteins | Botulinum toxin type A neurotoxin complex |
| Cross-product units | Not comparable or convertible | Not comparable or convertible |
| DeWitt Pharma availability | Available through professional account review | Not distributed by DeWitt Pharma |
The Xeomin duration compared to Botox is broadly similar. A 2023 head-to-head phase 3 study reported comparable glabellar-line response rates through day 120. That finding supports an overlapping duration, not a guaranteed four-month result.
Xeomin Results Longevity Depends on the Patient’s Recorded Response
Xeomin results longevity varies among patients, as the current label states. The treatment area and the patient’s observed response also affect how a clinic interprets the timeline.
Useful follow-up records include:
- treated area and baseline movement;
- patient-reported return of movement;
- clinician assessment of visible line change; and
- timing across treatment cycles.
For an aesthetic clinic, Xeomin duration of effect is better measured through consistent records than reduced to a fixed marketing promise. Our guide to Xeomin formulation and storage covers practical considerations without changing the duration limits described here.
Claims That Overstate Xeomin vs Botox Lasting Effects
Avoid claims that exceed current labeling or direct comparative evidence. Clinics should not state that:
- Xeomin always lasts longer than Botox Cosmetic;
- Botox Cosmetic always lasts longer than Xeomin;
- six months is routine for either product;
- units can be converted between products; or
- formulation alone proves a longer duration.
The Xeomin vs Botox lasting effects a patient notices may differ from the labeled population range. An independent Xeomin drug monograph is useful for general education, but current prescribing information should guide clinical decisions.
How Clinics Can Compare Duration Without Overpromising
We recommend a straightforward communication standard:
- State the labeled range and name the treatment area.
- Explain that individual duration varies.
- Record the return of movement and visible line change.
- Leave follow-up and retreatment decisions to a qualified clinician.
Duration is only one part of product selection. Formulation, labeled indications, storage, patient goals, and sourcing also matter. Our review of why some Texas med spas add Xeomin to their product mix examines those broader clinic considerations without claiming that Xeomin is universally superior.
Why Clinics Source Xeomin Through DeWitt Pharma
DeWitt Pharma supplies Xeomin to eligible licensed practices through a professional account-review process. Our Texas Xeomin product page explains that account credentials are reviewed before approval.
DeWitt Pharma does not distribute Allergan or AbbVie products, including Botox Cosmetic. Our role in this comparison is specific: we provide evidence-based information and professional sourcing access for Xeomin, but we do not supply or quote Botox Cosmetic.
Approved practices can review Xeomin pricing and product access after account approval.
Final Thoughts: Expect a Similar Three-to-Four-Month Window
The evidence-based answer to how long does Xeomin last vs Botox is about three to four months for either product. Xeomin labeling states up to 12 to 16 weeks. Botox Cosmetic labeling states approximately three to four months for glabellar lines.
DeWitt Pharma supports eligible practices with Xeomin sourcing, account review, and pricing access. Request Xeomin account review to evaluate product access for your practice.
Frequently Asked Questions
What should clinics know about Xeomin duration compared to Botox?
The labeled windows overlap. Xeomin typically lasts up to 12 to 16 weeks for upper facial lines, while Botox Cosmetic lasts approximately three to four months for glabellar lines. Response can vary between patients and treatment cycles.
How long does Xeomin last vs Botox for facial lines?
Both products generally fit a three-to-four-month planning window. Xeomin labeling covers upper facial lines, while the Botox Cosmetic duration statement specifically addresses glabellar lines. A clinician should set patient-specific expectations during consultation.
What affects Xeomin results longevity?
Fading often appears as a gradual return of movement rather than a single endpoint. The clinician should compare the patient’s report with the treated area, baseline findings, and changes documented during follow-up.
Who decides whether Xeomin or Botox Cosmetic is appropriate?
A qualified, licensed clinician makes this decision after assessing the patient, treatment area, goals, medical history, and current labeling. Duration can inform the consultation, but it cannot replace individualized clinical judgment.
What determines how long Xeomin works vs Botox?
Current labeling provides the starting range. The observed timeline depends on the individual response, treatment area, and when movement or lines return. Consistent follow-up records make the comparison more useful over time.
Can Xeomin or Botox Cosmetic last six months?
Some studies evaluate longer effects under specific protocols, but clinics should not describe six months as routine. Current labels support a more conservative three-to-four-month discussion for this comparison.
Does Xeomin always last longer because it lacks accessory proteins?
No. Xeomin’s formulation does not establish universal duration superiority. Current labeling and comparative evidence do not support a promise that Xeomin will outlast Botox Cosmetic for every patient or treatment area.
Are Xeomin vs Botox lasting effects identical for every patient?
No. Their expected ranges overlap, but wear-off patterns differ. Clinics should explain the range, document the patient’s response, and avoid guaranteeing identical timelines for the two products.
How often should patients return for follow-up?
The treating clinician should set follow-up according to clinical need and current labeling. A duration estimate should not become an automatic retreatment schedule or replace a patient-specific assessment.
Does a longer result always mean better value?
No. Value also depends on appropriate patient selection, treatment goals, authentic sourcing, documentation, and follow-up. Duration is one factor in a broader clinical and purchasing decision.
What should an aesthetic clinic track when reviewing Xeomin duration of effect?
Track the treated area, baseline movement, patient feedback, return of motion, and clinician assessment. Consistent documentation supports more accurate expectations across treatment cycles and gives staff a clearer counseling reference.
Can clinics request Xeomin sourcing information from DeWitt Pharma?
Yes. Eligible licensed practices can request account review and pricing access for Xeomin. DeWitt Pharma supplies Xeomin through its professional account process but does not distribute Botox Cosmetic or provide Botox pricing.
